Mehta Named Deputy Director at Miami Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MINESH MEHTA joined Miami Cancer Institute at Baptist Health South Florida as deputy director and chief of radiation oncology.

Mehta comes to Baptist Health from the University of Maryland School of Medicine, where he served as medical director of the Maryland Proton Treatment Center in Baltimore—the area’s first proton treatment center, which he helped to launch.

Mehta was also the university’s associate director of clinical research in the Department of Radiation Oncology. Prior to his time at Maryland, he held academic, research and administrative leadership positions at Northwestern University and the University of Wisconsin, where he was appointed chairman of the medical school’s Department of Human Oncology and led research studies, technology development and expansion at the University of Wisconsin Cancer Center. He also headed the university’s brain tumor program for more than 15 years. At the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, Mehta was co-director of the Radiation Oncology Residency Training Program.

The Miami Cancer Institute’s new $430-million proton therapy facility, opening in 2016 and located on the Baptist Hospital of Miami campus, expects to treat its first patient with proton therapy in 2017.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login